Ocular Therapeutix Q3 DEXTENZA revenue flat at $11.9M; net loss $24.2M; revises 2022 guidance to $48-52M

OCULAR THERAPEUTIX, INC

2022-Q3 EPS reported -$0.73 revenue$37,419,000

DEXTENZA net product revenue $11.9M in Q3 2022, flat YoY and down ~2% sequentially; 2022 guidance revised to $48-52M (10-20% growth).
Net loss $24.2M ($0.31/share) vs net income $2.7M ($0.03/share) in Q3 2021; includes $1.1M non-cash derivative liability adjustment.
OTX-TKI Phase 1 wet AMD interim: 80% rescue-free at 6 months, 73% at 7 months; Phase 2/3 planned for Q3 2023.
Phase 1 trial for diabetic retinopathy expected to start Q1 2023; OTX-TIC Phase 2 enrollment ongoing, topline data Q4 2023.
Cash and equivalents $121.0M as of Sep 30, 2022; sufficient to fund operations through 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

OCULAR THERAPEUTIX, INC updated its the quarter ended September 30, 2022 guidance (reaffirmed).

Period: the quarter ended September 30, 2022
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On November 7, 2022, Ocular Therapeutix, Inc. announced its financial results for the quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

OCULAR THERAPEUTIX, INC filing history →

Source: SEC EDGAR

accession 0001104659-22-115406

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.